Management Team

Denver Lough, M.D., Ph.D.

Chairman of the Board, President, Chief Executive Officer, Chief Scientific Officer

Dr. Denver Lough has always sought to investigate reality, pursue complex simplicity and develop a new paradigm in translational science. He is the President, Chief Executive Officer and Chairman of PolarityTE, and discoverer of micro-aggregate cell-based technologies for applications in the regeneration of functionally-polarized tissues. A prior member of the Johns Hopkins Plastic and Reconstructive Surgery Program, Dr. Lough's interests surround pragmatic tissue engineering, deployable regenerative material constructs, real-time assessment of cell-to-tissue fate, reactivity, functionality and, ultimately, therapeutic efficacy in complex living systems. Dr. Lough has significant experience with bench-to-bedside translational applications from assays/equipment to IRB/clinical trial development to scientific writing and presenting. He is well-respected within the field by thought leaders, with numerous national awards and accolades, as well as the ability to access a wide variety of clinical and research networks and markets. Dr. Lough is experienced with IP and patent evolution, investment strategy, regulatory pathway systems, CLIA/ GLP manufacturing platforms, legal due diligence and business development. Dr. Lough holds an M.D. and PhD. in Biochemistry, Molecular and Cell Biology from Georgetown University and was a Senior Plastic Surgery Resident at Johns Hopkins before leaving his position to start PolarityTE.

Edward Swanson, M.D.

Executive Vice President, Chief Operating Officer & Director

Dr. Edward W. Swanson graduated with honors from the School of Engineering and Applied Sciences at the University of Pennsylvania, with a BAS in Applied Sciences in Biomedical Sciences in May 2007. His bioengineering background provided a framework of investigative thinking and a solutions oriented approach throughout the rest of his career focused on bridging the gap between translational and clinical medicine. He went on to graduate from Harvard Medical School, receiving an MD with Honors in May 2012. Throughout his training at UPenn and Harvard Medical School, he gained insight into a variety of fields at the basic science level and clinical research translation, including pancreatic cancer, traumatic brain injury, nanotechnology, tissue engineering, and vascularized composite allotransplantation. Following medical school, he joined the Plastic Surgery Residency Program at The Johns Hopkins University School of Medicine, where he focused on both the translational research approaches in regenerative medicine and vascularized composite allotransplantation, as well as patient outcomes within craniofacial surgery. His interests and goals remain focused on impacting patients’ lives clinically by translating innovative technology. Given the opportunity to develop the radical technological platform of PolarityTE into a clinical reality, Dr. Swanson elected to leave his plastic surgery career in December 2016.

John Stetson

Executive Vice President, Chief Financial Officer & Director

Since September 2015, John Stetson has served as Chief Financial Officer and Executive Vice President of the Company. Since 2010, he has been the Managing Member of HS Contrarian Investments LLC, a private investment firm with a focus on early stage companies. In addition, Mr. Stetson served as Executive Vice President, Chief Financial Officer, and Director of Marathon Patent Group, Inc. (MARA), a NASDAQ listed patenting company from June 2012 to February 2015. Mr. Stetson received his BA in Economics from the University of Pennsylvania.

Cameron Hoyler, J.D.

General Counsel

Prior to joining PolarityTE, Mr. Hoyler was an attorney at the international law firm of King & Spalding LLP, where he practiced in the Life Sciences and Product Liability groups. Mr. Hoyler represented and counseled clients involved in disputes and transactions in a variety of settings, including product liability, employment, commercial, trademark, real estate, and insurance coverage matters.  While at King & Spalding, Mr. Hoyler devoted the vast majority of his practice to representing clients in the pharmaceutical and medical device industries, including Bristol-Myers Squibb Company, AstraZeneca Pharmaceuticals LP, and McKesson Corporation, in addition to working for clients in other highly-regulated industries, such as Chevron U.S.A. Inc. and Monsanto Company. He earned his Bachelor of Arts from the University of Pennsylvania, and his Juris Doctor from the University of San Francisco School of Law.

Jennifer Burdman, J.D.

Chief Intellectual Property Officer and Deputy General Counsel

Jennifer Burdman, Esq. is an intellectual property attorney specializing in IP procurement, protection, and enforcement. Ms. Burdman develops IP strategies and advises on their implementation in the business setting, including licensing deals and other strategic collaborations.  An experienced trial lawyer, she has successfully represented clients at the trial and appellate levels in complex, high-stakes litigations in patent infringement, trade secret misappropriation, and contractual matters involving IP rights.  In 2016, Ms. Burdman was profiled as a “Law360 Rising Star” and named to their 2016 Intellectual Property Editorial Advisory Board.  She was also named to Benchmark Litigation’s inaugural Under 40 Hot List in 2016, and again in 2017. The National Law Journal named her a 2015 “Rising Star" in Washington, D.C.

Ms. Burdman’s thought leadership in the intellectual property field has been featured in the Bloomberg BNA Daily Report for Executives and the Intellectual Property & Technology Law Journal, among others. Noteworthy cases include a jury verdict of patent infringement related to the preservation of soft tissue grafts resulting in over $34 million in damages, a jury verdict of willful misappropriation of trade secrets relating to Kevlar with damages of over $900 million, and the successful defense of The Regents of the University of California against a patent licensee seeking expanded rights relating to its sponsored research and license agreements relating to compounds for the treatment of prostate cancer.

Ms. Burdman graduated from Dartmouth College with an A.B. in biochemistry and molecular biology and received her J.D. from Fordham University School of Law.

Stephen Milner, MD, DDS, DSc, FRCSE, FACS

Chief Clinical Officer

Stephen Milner MB.BS, BDS, DSc, FRCS(Ed), FACS is Professor of Plastic and Reconstructive Surgery and Pediatrics at Johns Hopkins University School of Medicine, Director of the Johns Hopkins Burn Center and Professor at the Bloomberg School of Public Health. He also serves as Director of the Michael D Hendrix Burn Research Center, Adjunct Professor Uniformed Services University of the Health Sciences and formerly Honorary Civilian Consultant Advisor to the British Army in Plastic Surgery and Burns.

Dr. Milner is a graduate of Guy's Hospital Medical and Dental Schools. He trained in general surgery in London and at the Massachusetts General Hospital. After service as lieutenant colonel in the Royal Army Medical Corps, where he served on active duty in Operation Desert Storm, he completed a plastic surgery residency through the University of Texas and the Shriner's Burn Institute in Galveston. In 2010 he was awarded an Honorary Doctorate of Science from the University of Glamorgan, UK in recognition for his work in burns.

In 2012 he was awarded a Humanitarian Award from the James R. Jordan Foundation and in 2013 was given the Sushruta-Guha Lectureship and medal in Plastic Surgery and Wound Healing from the Royal College of Surgeons of Edinburgh. He has written more than 120 peer reviewed articles amongst his numerous publications and is founding editor of one of the first open access journals, ePlasty.

Michael W. Neumeister, MD, FRCSC, FACS

Chief Medical Officer

Dr. Neumeister is Professor & Chairman of the Department of Surgery and The Elvin G. Zook Endowed Chair in Plastic Surgery at Southern Illinois University School of Medicine in Springfield, IL.  He received his medical degree from the University of Toronto and previously completed a degree in physiology and pharmacology at the University of Western Ontario.  Dr. Neumeister began his residency at Dalhousie University in Halifax, Nova Scotia in general surgery and went on to complete his plastic surgery residency at the University of Manitoba.  He continued his training as a microsurgery fellow at Harvard University’s Brigham & Women’s Hospital in Boston and completed a one year hand and microsurgery fellowship at Southern Illinois University School of Medicine.  Dr. Neumeister is board certified in plastic surgery by the Royal College of Surgeons of Canada and the American Board of Plastic Surgery.  He has also received his Certificate in Surgery of The Hand (SOTH). Dr. Neumeister has received awards for presentations given regionally, nationally and internationally, has over 150 book chapters and articles, and has multiple research interests in tissue engineering and regenerative medicine.  Dr. Neumeister is the Editor in Chief of the official AAHS journal HAND.  He is the past President of the American Society of Reconstructive Microsurgery, American Association for Hand SurgeryThe Plastic Surgery Foundation (The Research Body of The American Society of Plastic Surgeons)Plastic Surgery Research Council, and the Midwest Association of Plastic Surgeons. He is a leader in translational regenerative medicine research and hopes to utilize his wide network of clinical thought leaders and practical viewpoint on the application of the PolarityTE Platform technology to make it a clinical reality.